Special Issue "Chronic Lymphocytic Leukemia"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2020).
Interests: chronic lymphocytic leukemia; Richter’s syndrome; tumor microenvironment; cancer genetics; translational medicine
Interests: chronic lymphocytic leukemia; cancer genetics; tumor microenvironment; molecular biology
Interests: chronic lymphocytic leukemia; therapy; prognostic factors; elderly patients
In the last decades, several discoveries have increased our understanding of the genetic and molecular mechanisms contributing to the onset and progression of chronic lymphocytic leukemia (CLL). Recently published data have indicated important pathogenetic steps involved in the survival and progression of CLL cells, and identified markers that are critical for better stratification of patients at diagnosis. The portfolio of therapeutic opportunities available to treat CLL patients has grown tremendously, allowing a more tailored approach depending on the genetic and molecular features of each patient.
This Special Issue will focus on chronic lymphocytic leukemia and its transformation to an aggressive lymphoma, Richter’s Syndrome. We welcome contributions focusing on the key genetic and molecular changes that contribute to disease development and/or drive its progression, as well as articles that investigate available therapeutic options.
Dr. Tiziana Vaisitti
Dr. Francesca Arruga
Dr. Alessandra Ferrajoli
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chronic lymphocytic leukemia
- Richter’s syndrome
- gene mutations
- signaling pathways
- target therapy